Heart failure with iron deficiency anemia
This is a randomized, double blind, placebo-controlled study to investigate the efficacy and safety of Injectafer® (ferric carboxymaltose) as treatment for heart failure with iron deficiency. Study drug administration will occur as two intravenous doses every six months for duration of study.
Peter Eckman, MD
Luitpold Pharmaceuticals, Inc.